(Q36577856)

15 August 2017

1 reference

title

The metabolic effects of antipsychotic medications (English)

1 reference

15 August 2017

John W Newcomer

1

1 reference

ORCID Public Data File 2021

author name string

Dan W Haupt

series ordinal

2

1 reference

PubMed ID

16933585

15 August 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Canadian Journal of Psychiatry

15 August 2017

1 reference

15 August 2017

51

1 reference

15 August 2017

480-491

1 reference

15 August 2017

8

1 reference

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

15 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Management of dyslipidemia in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Health care and health status and outcomes for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Standards of medical care for patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Medical hazards of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Diabetes mellitus in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Excess mortality of schizophrenia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Abnormalities in glucose regulation associated with mental illness and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Amisulpride is an "atypical" antipsychotic associated with low weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Diabetic ketoacidosis associated with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Clozapine use and risk of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Antipsychotic-induced type 2 diabetes: evidence from a large health plan database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A crossover study on lipid and weight changes associated with olanzapine and risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Excess mortality in depression: a meta-analysis of community studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

One- and two-year change in body composition as measured by DXA in a population-based cohort of older men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Weight stability masks sarcopenia in elderly men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Differential effects of BMI on diabetes risk among black and white Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

The perils of portliness: causes and consequences of visceral adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Open-label study of olanzapine in children with pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

Syndrome X: 10 years after

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370605100803

10.1177/070674370605100803

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16933585